CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader
in the field of stapled peptides developing therapeutics for cancers and other diseases, today announced that two abstracts on the
Company’s lead product candidate, ALRN-6924, have been accepted for oral presentation at the 59th American Society of Hematology
(ASH) Annual Meeting to be held in Atlanta, Georgia from December 9-12.
“We are pleased that the scientific and medical communities continue to recognize our dual-inhibitor stapled peptide
therapeutic, ALRN-6924, and its potential impact in restoring the function of p53 to treat cancers,” said Joseph A. Yanchik III,
President and Chief Executive Officer. “These two ASH abstracts selected for oral presentations closely follow on our clinical data
presentation at ASCO in June, which was selected for an oral presentation as well as the Best of ASCO program.”
The oral presentations will highlight preclinical data from Aileron’s collaboration with the Dana-Farber Cancer Institute on
ALRN-6924 in peripheral T-cell lymphoma (PTCL), and from its collaboration with Albert Einstein College of Medicine on
ALRN-6924 in acute myeloid leukemia (AML).
Presentation Details
Presentation Title: “In Vitro and Preclinical In Vivo Evidence Support MDMX/MDM2 as Common
Vulnerabilities Across TP53-Wild-Type T-Cell Lymphomas That Are Targetable with the Alpha-Helical P53 Stapled Peptide ALRN-6924”
Session Name: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Novel Targeted therapies for
Non-Hodgkin's Lymphomas
Session Date: Monday, December 11, 2017
Session Time: 7:00 a.m. - 8:30 a.m. EST
Presentation Time: 7:00 a.m. EST
Presentation Title: “Dual Inhibition of MDMX and MDM2 Using an Alpha-Helical P53 Stapled Peptide (ALRN-6924) As
a Novel Therapeutic Strategy in Acute Myeloid Leukemia”
Session Name: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Novel Therapeutics and
Mechanisms of Resistance in Myeloid Disease
Session Date: Monday, December 11, 2017
Session Time: 4:30 p.m. – 6:00 p.m. EST
Presentation Time: 5:00 p.m. EST
About ALRN-6924
ALRN-6924 is a first-in-class product candidate designed to reactivate wild type p53 tumor suppression by disrupting the
interactions between the two primary p53 suppressor proteins, MDMX and MDM2. Aileron believes ALRN-6924 is the first and only
product candidate in clinical development that can equipotently bind to and disrupt the interaction of MDMX and MDM2 with
p53. Based on preclinical data and preliminary evidence of safety and anti-tumor activity in its ongoing clinical trials,
there may be a significant opportunity to develop ALRN-6924 as a monotherapy or combination therapy for a wide variety of solid and
liquid tumors. ALRN-6924 is currently being evaluated in multiple clinical trials for the treatment of acute myeloid
leukemia (AML), advanced myelodysplastic syndrome (MDS) and peripheral T-cell lymphoma (PTCL). For information about its
clinical trials, please visit www.clinicaltrials.gov.
About Aileron Therapeutics
Aileron is a clinical-stage biopharmaceutical company advancing stapled peptides, a novel class of therapeutics for cancers and
other diseases. Stapled peptides are chemically stabilized alpha-helical peptides that are modified to improve their stability and
cell penetrability while maintaining high affinity for large protein surfaces. Our goal is to use our proprietary stapled peptide
drug platform to create first-in-class therapeutics, like ALRN-6924, that may be able to address historically undruggable targets
and complex mechanisms that underlie many diseases with high unmet medical need. Our platform enables us to chemically stabilize
and improve the performance and activity of a broad range of alpha-helical peptides that can potentially activate and inhibit key
cellular functions that are otherwise difficult to target with existing drug technologies, including small molecules and monoclonal
antibodies. For more information, visit www.aileronrx.com.
Forward-Looking Statement
Statements in this press release about Aileron's future expectations, plans and prospects, as well as any other
statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The
Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the Company’s
cash forecast, the sufficiency of the Company’s cash resources and the timing of clinical trial enrollments and data. The words
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important
factors, including whether Aileron’s cash resources will be sufficient to fund its continuing operations for the periods and/or
trials anticipated; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in
future clinical trials; whether Aileron’s product candidates will advance through the clinical trial process on a timely basis, or
at all; whether the results of such trials will warrant submission for approval from the United States Food and Drug
Administration or equivalent foreign regulatory agencies; whether Aileron's product candidates will receive approval
from regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully
distributed and marketed; and other factors discussed in the "Risk Factors" section of Aileron's quarterly report on Form
10-Q for the period ended June 30, 2017, filed on August 10, 2017, and risks described in other filings that Aileron may make with
the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the
date hereof, and Aileron specifically disclaims any obligation to update any forward-looking statement, whether because
of new information, future events or otherwise.
Source: Aileron Therapeutics
Media: BMC Communications Brad Miles, 646-513-3125 bmiles@bmccommunications.com
